-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Our 12-month target is $89, raised from $85, applying a 20.1x multiple to our 2026 EPS estimate (down $0.04 to $4.42; 2027 estimate down $0.05 to $4.78), a small premium to IFF's three-year average forward P/E of 19.7x. Our valuation reflects the company's ongoing strategic transformation toward a higher-margin, innovation-driven portfolio, and we view the multiple as appropriate, given management's progress in repairing the balance sheet after years of value-destructive M&A decisions. IFF's Food Ingredients divestiture appears to be on track, and the company recently completed the sale of its commodity soy crush, concentrates, and lecithin business to Bunge. Negatively, we see near-term challenges for the Scent business, with inflation in logistics and commodity costs from the geopolitical conflict in the Middle East weighing on fine fragrances. However, IFF expects the Health business to return to growth in H2 2026 and improve into 2027, led by a strengthening pipeline.